Our Board of Directors is comprised of our Chairman and Independent Non-Executive Director; 2 Executive Directors,our Chief Executive and Chief Financial Officer: and 2 additional Independent Non-Executive Directors. All 5 Directors bring skill and experience of strategic and operation delivery in growing small businesses, biotechnology and diagnostics, and public company governance.

Peter Harrison

Chief Executive Officer

Peter has worked in the field of antibody technology since 1986 and has extensive experience of the development and commercialisation of antibody technologies. He graduated in Natural Sciences from Clare College Cambridge in 1980 and joined the graduate training scheme at Shell Chemicals UK Ltd. In 1986 he joined Celltech Ltd to manage their contract antibody production business and in 1991 he joined KS Biomedix Ltd and helped to establish sheep monoclonal antibody technology at their Farnham research laboratory. Following the acquisition of KS Biomedix Limited by Xenova plc in 2003, he led a management buy-out that resulted in the formation of Bioventix and he has led the subsequent commercial development of the Company.

Ian Nicholson

Chairman and Independent Non-Executive Director

Ian was appointed as Non-Executive Chairman of Bioventix in November 2004. Ian is an Operating Partner at Advent Life Sciences LLP and a Trustee of LifeArc, a leading UK medical charity. From 2013 to 2021 Ian was Chief Executive Officer of F2G Ltd an antifungal drug development company and from 2004 to 2012 Ian was Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company. He previously held the position of Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian is a member of the Audit Committee, the Remuneration Committee and the Nominations Committee.

Jo Pisani

Independent Non-Executive Director

Jo was appointed as a Non-Executive Director of Bioventix in May 2023. She is a Chartered Engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She held roles for both GSK and BP in strategy, commercial and operational functions before working in strategic consultancy latterly leading PwC’s UK Pharmaceutical and Life Sciences practice assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions. Jo is a passionate supporter of critical public health issues, such as tackling dementia, rare diseases and anti-microbial resistance. She focuses on supporting charities, universities and business start-ups. She is chair of Birmingham’s Precision Health Technology Accelerator and chairs the Advisory Board for London’s MedCity. Jo also serves on the boards of the UK Dementia Research Institute, LifeArc, The RSA Group, London and Partners and Beacon. She is also a Non-Executive Director and strategic advisor to biotech companies in the UK, Finland and Spain. Jo chairs the Bioventix plc Audit Committee; she is also a member of both the Remuneration and Nominations committee.

Bruce Hiscock

Chief Financial Officer

Bruce was appointed to the Board in 2020. He is a member of the Institute of Chartered Accountants of Scotland (ICAS) and was previously CEO and CFO of everyLIFE Technologies Limited, a technology business developing and delivering digital care planning SaaS solutions to social care providers. Prior to this he was the Managing Director of MITIE Security Systems Limited, the CEO of Protec plc, an AIM listed security and technology services business, and has held several CFO roles at both fast-growing listed and private companies over a 30-year career.

Nicholas Mccooke

Independent Non-Executive Director

Nick was appointed as Non-Executive Director of Bioventix in 2014 when the Company first listed on AIM. Nick has worked in the biotech industry for over 30 years and is now an independent consultant providing operational, strategic and commercial advice and hands-on support to biotech companies. He has led several successful companies. He was the founding CEO of Solexa, the Cambridge University spin-out where he built the team that invented and developed Next Generation DNA sequencing. Subsequently he was CEO of Belgian company Pronota, which translated novel protein biomarkers into diagnostics, and where he gained much knowledge and expertise in the diagnostic development and market access process. Most recently he was CEO of DNA sequencing technology company Longas Technologies pty Ltd. He has an MBA from the London Business School. Nick is Chairman of the Remuneration Committee and Nomination Committee and is a member of the Audit Committee.

Our People

A small team of dedicated scientists, committed to improving diagnostic tests and clinical outcomes for people around the world.